Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 67 of 91 for:    cervarix

Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03180034
Recruitment Status : Recruiting
First Posted : June 8, 2017
Last Update Posted : April 5, 2019
Sponsor:
Collaborator:
Bill and Melinda Gates Foundation
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

Certain types of human papillomavirus (HPV) cause almost all cases of cervical cancer. Vaccines that protect against HPV can substantially reduce the risk of cervical cancer. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer. HPV vaccines are expensive-many countries cannot afford them-more than one dose is needed, and giving multiple doses is difficult. Researchers want to find out if one dose prevents HPV infection. If it does, more people might get the vaccine.

Objective:

To find out if giving only one dose of either the Cervarix or Gardasil9 HPV vaccines work the same as giving two doses of these vaccines to young women.

Eligibility:

Females ages 12-20 who live in Costa Rica.

Design:

There are two components to the study: (1) a controlled, randomized, double-blinded non-inferiority clinical trial to compare one-dose to two-dose vaccination; and (2) a concurrent epidemiologic survey for HPV status among unvaccinated women.

The trial will enroll twenty thousand girls 12 to 16 years old residing in Costa Rica. Participants will be randomized in two stages to one of four arms (one dose of the bivalent vaccine, two doses of the bivalent vaccine, one dose of the nonavalent vaccine and two doses of the nonavalent vaccine); the first randomization at enrollment will assign participants to one of the two study vaccines and at the second visit they will be randomized to one or two doses. Girls randomized to the one dose arm will receive an active control (i.e.: Tdap) at the time of the second vaccine dose. After vaccination, girls will be followed every six months for four years.

The epidemiologic HPV survey will enroll a group of unvaccinated girls from the same geographic areas; they will range in age from 17 to 20. These women will attend two study visits six months apart to determine their HPV DNA status, there will be no additional followup. These women will be offered HPV vaccination at the enrollment and six-month study visits.

At each visit, participants will fill out a questionnaire and give a urine sample. They may give blood samples. The older participants will use a swab to collect cervical cells from their vagina....


Condition or disease Intervention/treatment Phase
Cervical Cancer Cervical HPV Infection Anti-HPV Antibody Patterns Sexually Transmitted Infections Biological: Cervarix Biological: Gardasil 9 Phase 4

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study
Actual Study Start Date : November 29, 2017
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2024

Arm Intervention/treatment
Experimental: Arm 1 (Gardasil 9 1-Dose Group)
5000 girls ages 12-16 years
Biological: Gardasil 9
Vaccine indicated in females 9 through 26 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58; and Genital warts (condyloma acuminata) caused by HPV types 6 and 11. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 months (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for three doses (0.5- mL each) intramuscular injection at 0, 2 months, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose intervention will be in 5000 girls ages 12-16 years.

Experimental: Arm 2 (Cervarix 1-Dose Group)
5000 girls ages 12-16 years
Biological: Cervarix
Vaccine indicated in females 9 through 25 years of age for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: Cervical, vulvar, vaginal, and anal cancer cervical cancer; cervical intraepithelial neoplasia (CIN) Grade2 or worse and adenocarcinoma in situ; and cervical intraepithelial neoplasia (CIN) Grade 1 caused by Human Papillomavirus (HPV) types 16 and 18. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for use in females 9 through 25 years of age. Approved for three doses (0.5-mL each) by intramuscular injection at 0, 1, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose

Active Comparator: Arm 3 (Gardasil 9 2-Dose Group)
5000 girls ages 12-16 years
Biological: Gardasil 9
Vaccine indicated in females 9 through 26 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58; and Genital warts (condyloma acuminata) caused by HPV types 6 and 11. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 months (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for three doses (0.5- mL each) intramuscular injection at 0, 2 months, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose intervention will be in 5000 girls ages 12-16 years.

Active Comparator: Arm 4 (Cervarix 2-Dose Group)
5000 girls ages 12-16 years
Biological: Cervarix
Vaccine indicated in females 9 through 25 years of age for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: Cervical, vulvar, vaginal, and anal cancer cervical cancer; cervical intraepithelial neoplasia (CIN) Grade2 or worse and adenocarcinoma in situ; and cervical intraepithelial neoplasia (CIN) Grade 1 caused by Human Papillomavirus (HPV) types 16 and 18. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for use in females 9 through 25 years of age. Approved for three doses (0.5-mL each) by intramuscular injection at 0, 1, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose

No Intervention: Epidemiologic HPV Survey Arm
4000 Unvaccinated women ages 17 to 20 (1000 women between 17 and 18; 1000 women between 18 and 19; 1000 women between 19 and 20; and 1000 women age 20); Followed for six months



Primary Outcome Measures :
  1. Evaluate non-inferiority of one compared to two vaccination doses of Cervarix in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination [ Time Frame: 48 months ]
    Evaluate non-inferiority of one compared to two vaccination doses of Cervarix in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination

  2. Evaluate non-inferiority of one compared to two vaccination doses of Gardasil 9 in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination. [ Time Frame: 48 months ]
    Evaluate non-inferiority of one compared to two vaccination doses of Gardasil 9 in the prevention of new HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination

  3. Evaluate one dose of Cervarix compared to no vaccination in the protection against HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination. [ Time Frame: 48 months ]
    Evaluate one dose of Cervarix compared to no vaccination in the protection against HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination

  4. Evaluate one dose of Gardasil 9 compared to no vaccination in the protection against HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination. [ Time Frame: 48 months ]
    Evaluate one dose of Gardasil 9 compared to no vaccination in the protection against HPV16/18 cervical HPV infections that persist 6+ months in girls ages 12-16 years at vaccination


Secondary Outcome Measures :
  1. Compare immunogenicity via measurement of serum antibodies between girls who received one or two doses of Cervarix. [ Time Frame: 48 months ]
  2. Compare immunogenicity via measurement of serum antibodies between girls who received one or two doses of Gardasil 9. The primary focus will be on HPV16/18, but antibodies against additional HPV types included Gardasil 9 will also be investigate... [ Time Frame: 48 months ]
  3. Demonstrate non-inferiority of one versus two doses of Gardasil 9 in the prevention of any new vaccinetype HPV infection (i.e., aggregate HPV 16/18/31/33/45/52/58) that persist 6+ months. [ Time Frame: 48 months ]
  4. Demonstrate non-inferiority of one versus two doses of Cervarix in the prevention of any new carcinogenic HPV cervical infection (vaccine and/or non-vaccine types) that persists 6+ months. [ Time Frame: 48 months ]
  5. Demonstrate non-inferiority of one versus two doses of Gardasil 9 in the prevention of any new carcinogenic HPV cervical infection (vaccine and/or non-vaccine types) that persists 6+ months. [ Time Frame: 48 months ]
  6. Conduct a cost and cost-effectiveness evaluation of HPV vaccination with one versus two doses of the Gardasil 9 and Cervarix in the setting of Costa Rica. [ Time Frame: 48 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Girls will be deemed eligible if they are:

  • Female;
  • Aged between 12 and 16 years inclusive
  • Living in the study area without plans to move outside the country in the next six months;
  • Able to communicate with study personnel;
  • Willing to participate in the study and sign the informed assent;
  • Supported in study participation by at least one of their parents (or guardians), who is willing to sign the informed consent document; and,
  • In good health as determined by a medical history (physical exam will be conducted if necessary per the doctor s criterion).

EXCLUSION CRITERIA:

Girls will be excluded from enrollment if:

-They have a diagnosis of an autoimmune, degenerative, or neurological disease without treatment or adequate control; a progressive or severe neurological disease; a genetic immunodeficiency; or any other serious chronic disease without treatment and / or adequate control that, according to the principal investigator or designee, for which vaccination is contraindicated (NOTE: Potential participants with these conditions can

be included after consultation with the external medical advisor of the study or with an appropriate specialist);

  • They are allergic to one of the vaccine components, yeast, or latex;
  • The clinician determining the eligibility in agreement with principal investigator considers that there is a reason that precludes participation;
  • They have been vaccinated against HPV;
  • The girl or her parent/legal guardian does not have an identification document.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180034


Contacts
Layout table for location contacts
Contact: Aimee R. Kreimer, Ph.D. (240) 276-7102 kreimera@mail.nih.gov

Locations
Layout table for location information
Costa Rica
Agencia Costarricense de Investigaciones Biomedicas (ACIB) Recruiting
Liberia, Costa Rica
Contact: Paula Gonzalez    Not Listed    pgonzalez@proyectoguanacaste.org   
Sponsors and Collaborators
National Cancer Institute (NCI)
Bill and Melinda Gates Foundation
Investigators
Layout table for investigator information
Principal Investigator: Aimee R. Kreimer, Ph.D. National Cancer Institute (NCI)

Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03180034     History of Changes
Other Study ID Numbers: 999917108
17-C-N108
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: April 5, 2019
Last Verified: April 2, 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Human Papillomavirus
Cervical Cancer
Costa Rica
Fewer Doses
HPV-Associated Cancers

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Uterine Cervical Neoplasms
Sexually Transmitted Diseases
Papillomavirus Infections
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Virus Diseases
Genital Diseases, Male
DNA Virus Infections
Tumor Virus Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs